Hot Keywords
non-alcoholic fatty liver disease epidemiology microenvironment nonalcoholic steatohepatitis transplantation cholangiocarcinoma direct-acting antiviral immunotherapy hepatitis B hepatitis C liver resection imaging cancer stem cell diagnosis gene cirrhosis biomarker recurrence

Topic: Liver Transplant for HCC: Short-Term and Long-Term Problems during Follow-Up

A special issue of Hepatoma Research

ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)

Submission deadline: 30 Nov 2020

Guest Editor(s)

  • Geoff McCaughan, MD, PhD
    Centenary Research Institute, Australian National Liver Transplant Unit, Royal Prince Alfred Hospital, The University of Sydney, Sydney, Australia.

    Website | E-mail

Special Issue Introduction

Liver Transplantation is now an established therapy for patients with known Hepatocellular Carcinoma (HCC). Criteria for patient selection vary across several countries and continents ranging from the well established Milan criteria to University of San Francisco California Criteria and the more recently modified criteria such as the Metro ticket concept designed to include serum alpha-fetoprotein levels and hence aspects of tumour biology in patient selection. HCC is a complication of all forms of cirrhosis and continues to be a significant problem in patients with chronic HCV-associated cirrhosis even in those who have cleared the virus .With the emergence of non-alcoholic liver disease as an increasing cause of HCC and an indication for liver transplantation, post-transplant metabolic issues in HCC patients need to be monitored and addressed. Hepatitis B virus-associated HCC means that prevention of HBV recurrence is a major issue for HCC patients undergoing liver transplantation in many parts of the world .HCC also complicates autoimmune disease such as Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, and Autoimmune Hepatitis.Hence, recurrence of these diseases may also pose a problem in liver transplantation for HCC. All these issues are addressed in this issue by international leading experts.In addition, common problems that effect all patients such as early allograft dysfunction, allograft rejection, acute kidney injury as well as long term problems such as ischemic biliopathy and extrahepatic malignancy in long-term immunosuppressed patients are discussed. Hence, this issue covers all the major topics that need to be understood in managing patients with HCC undergoing liver transplantation.


Short-term problems
1.Primary non-function and Early allograft dysfunction
2.Acute kidney injury: Prevention and effect on immunosuppression
3.Acute allograft rejection: Diagnosis, risk factors and treatment
4.Prevention of HBV recurrence
5.Minimisation of HCC recurrence and treatment

Long-term problems
1.Ischemic Biliopathy: Risk factors and management
2.Extrahepatic malignancy: Risks and prevention
3.Recognition and management of the metabollic syndrome
4.Recurrent Autoimmune diseases(PBC/PSC/AIH)


1. Ming-Ling Chang  Division of Hepatology, Department of Gastroenterology and Hepatology, Liver Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
2. Michal Grat  Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
3. Andrew L Mason  Division of Gastroenterology and Hepatology, University of Alberta, Edmonton, Alberta, Canada.
4. James Fung  Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
5. Claire Vajdic  Centre for Big Data Research in Health, University of New South Wales, Kensington, NSW, Australia.
6. Stephen J. Wigmore  Department of HPB/Transplant Surgery, Royal Infirmary of Edinburgh, The University of Edinburgh, Edinburgh, UK.
7. Michele Molinari  Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
8. Kamleshsingh Shadhu  Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University & Jiangsu Province Hospital, Nanjing, Jiangsu, China.
9. Eguchi, Susumu  Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
10. Hajime Matsushima  Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
11. Andrew J. Muir  Division of Gastroenterology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
12. Łukasz Masior  Department of General, Vascular and Oncological Surgery, Medical University of Warsaw, Warsaw, Poland.
13. Anthony Michaels  Department of Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
14. Coleman I Smith  MedStar Georgetown Transplant Institute, Georgetown University School of Medicine, Washington, DC, USA.
15. Luciana Costa Faria  Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brasil.
16. Michael Ronan Lucey  Division of Gastroenterology and Hepatology, University of Wisconsin, School of Medicine and Public Health, Madison, WI, USA.
17. Parul D Agarwal  Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
18. Mohamed S. Rela  Institute of Liver Studies, King's College Hospital, London, UK.
19. Aiwu Ruth He  Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA.
20. Oya M. Andacoglu  Abdominal Transplant Surgeon, Koc University, Live Donor Liver Transplantation Unit, Istanbul, Turkey.
21. Ryan A. Helmick  Division of Transplant Surgery, Methodist University Hospital Transplant Institute, Memphis, TN, USA.
The list is arranged in no particular order and being updated.

Submission Deadline

30 Nov 2020

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 30 Nov 2020
Contacts: Ada Zhong, Assistant Editor,

Published Articles

© 2016-2021 OAE Publishing Inc., except certain content provided by third parties